Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Diagnostics for the early detection
and prevention of colon cancer
J.P. Morgan Healthcare Conference
January 2015
Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of
the S...
FDA
approval
A milestone year 2014
2
Launch
Q4: 4,000+
tests completed
Medicare
coverage &
$493
reimbursement
OUR FIRST MISSION
To partner with healthcare providers,
payers, patients and advocacy
groups to help eradicate colorectal
...
136,830
Source: ACS Cancer Facts & Figures 2014; all figures annual
Ovary Prostate Pancreas Breast LungCervix
14,270
29,48...
5
Source: J Natl Cancer Inst. 2009; 101:1225-1227 (Itzkowitz)
– Journal of the National Cancer Institute
Major opportunity t...
Detection and removal of polyps prevents cancer
Pre-cancerous polyp
Stages of colon cancer
10-15
years
7
Sources: N Engl J...
Detecting colorectal cancer early is important
9out of 10
Diagnosed early stages (I-II)
Survive 5 years
1out of 10
Diagnos...
Rising cost of colorectal cancer treatment
9
2010 2015 2020
Projected
annual
treatment costs
in 2020
$20B
$14B
Source: J N...
American Cancer Society goal: 80% by 2018
Colorectal
Cervical
Cancer screening rates
83%
65%
10 Source: ACS Cancer Prevent...
Cologuard in practice guidelines
*Guidelines based on a previous stool DNA test developed by Exact Sciences
Update
America...
A powerful value proposition to physicians & patients
①Cologuard is patient friendly
②Cologuard is highly effective
③Activ...
FPO
Cologuard: FDA-approved, non-invasive screening test
13
14 Source: N Engl J Med 2014;370:1287-97. DOI: 10.1056/NEJMoa1311194 (Imperiale)
Physician & patient engagement team
• Remove follow-up
hassle from
physicians
• 24/7 contact center
• Active patient
remin...
16
Sales & marketing strategy
PHYSICIANS
140 person sales team
Med journal ads
Hyper-targeted digital
Direct mail/email
PA...
Experienced, focused sales team
• 100 primary care
reps, expanding in
first half of 2015
• 11 health system
reps
• Average...
Key Cologuard launch metrics
18
①Q4 2014 revenue: $1.5 million
②More than 4,000 ordering
physicians
③75% patient complianc...
Cologuard public relations
19
Active effort to raise awareness of Cologuard
• Cologuard featured in more than 1,000 unique...
Physician enrollment & ordering increasing
20
9,800+
physicians
enrolled
42%
ordering
Data as of December 31, 2014
Sales & marketing tactics working
% of Ordering Providers % of Orders
68%
32%
51
%
49%
21
Providers converted
by sales for...
37%
26%
10% 75%
Returned with no
compliance call
Returned after
compliance call 1
Returned after
compliance call 2
Overall...
Cologuard having positive effect on screening compliance
Half of Cologuard users have never had a colonoscopy
Never
Screen...
24
Impact of FIT/FOBT usage on ordering behavior
*High FIT/FOBT defined as ≥100 FIT/FOBT tests annually
More Cologuard ord...
Medicare
43%
Commercial
Insurance
40%
Medicaid
4%
Military
2%
Uninsured
10%
Reimbursement efforts focused on commercial in...
Factors for Cologuard success in 2015 and beyond
26
Expanding reach and frequency with
providers
1
USPSTF guideline inclus...
European launch of Cologuard
27
• Large, addressable market
• High colon cancer rate
(152K deaths annually)
• Low screenin...
Other
Lymphoma
Leukemia
Urinary
Breast
Genital
Respiratory
GI
145K
Source: American Cancer Society 2013, Surveillance Rese...
Exclusive Mayo Clinic collaboration on
early detection of GI cancers
29
Colorectal
Esophageal
Pancreatic
• Expand indicati...
Financials and key milestones
• Cash balance of $211 million as of September 30, 2014
• $100-million offering closed in De...
31
Grow
Cologuar
d
Develop
Pipeline
World
Class
Service
Our goals for 2015
Upcoming SlideShare
Loading in …5
×

Exact Sciences 2015 J.P Morgan Healthcare Conference Presentation

1,890 views

Published on

Exact Sciences CEO Kevin Conroy delivers an update on the commercial launch of Cologuard and tells the Exact Sciences story at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco California. The presentation took place January 14, 2015.

  • Be the first to comment

Exact Sciences 2015 J.P Morgan Healthcare Conference Presentation

  1. 1. Diagnostics for the early detection and prevention of colon cancer J.P. Morgan Healthcare Conference January 2015
  2. 2. Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. Forward-looking statements in this news release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expectations concerning our ability to secure and the timing of reimbursement for our Cologuard test, our estimated reimbursement amounts, our estimates of the available market size and our potential penetration, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Safe Harbor Statement 1
  3. 3. FDA approval A milestone year 2014 2 Launch Q4: 4,000+ tests completed Medicare coverage & $493 reimbursement
  4. 4. OUR FIRST MISSION To partner with healthcare providers, payers, patients and advocacy groups to help eradicate colorectal cancer
  5. 5. 136,830 Source: ACS Cancer Facts & Figures 2014; all figures annual Ovary Prostate Pancreas Breast LungCervix 14,270 29,480 39,590 40,430 50,310 159,260 4,020 Annual U.S. cancer mortality Colorectal cancer: America’s second-leading cancer killer new U.S. cases U.S. deaths 50,310 Colorectal 4
  6. 6. 5
  7. 7. Source: J Natl Cancer Inst. 2009; 101:1225-1227 (Itzkowitz) – Journal of the National Cancer Institute Major opportunity to improve colorectal cancer screening The most preventable, yet least prevented cancer. 6
  8. 8. Detection and removal of polyps prevents cancer Pre-cancerous polyp Stages of colon cancer 10-15 years 7 Sources: N Engl J Med 2012;366:687-96 (Zauber); Gastro 1997;112:594-692 (Winawer)
  9. 9. Detecting colorectal cancer early is important 9out of 10 Diagnosed early stages (I-II) Survive 5 years 1out of 10 Diagnosed Stage IV Survive 5 years 8 Source: SEER 18 2004-2010
  10. 10. Rising cost of colorectal cancer treatment 9 2010 2015 2020 Projected annual treatment costs in 2020 $20B $14B Source: J Natl Cancer Inst. 2011; 103:1-12 (Mariotto)
  11. 11. American Cancer Society goal: 80% by 2018 Colorectal Cervical Cancer screening rates 83% 65% 10 Source: ACS Cancer Prevention & Early Detection Facts & Figures 2013; Company estimates 14m more screened
  12. 12. Cologuard in practice guidelines *Guidelines based on a previous stool DNA test developed by Exact Sciences Update American Cancer Society American College of Gastroenterology* 2014 U.S. Preventive Services Task Force 2009 Expected 2015 Guideline Under ACA, if USPSTF issues A/B rating then all commercial payers must cover Cologuard 11
  13. 13. A powerful value proposition to physicians & patients ①Cologuard is patient friendly ②Cologuard is highly effective ③Active engagement by Exact Sciences drives patient compliance 12
  14. 14. FPO Cologuard: FDA-approved, non-invasive screening test 13
  15. 15. 14 Source: N Engl J Med 2014;370:1287-97. DOI: 10.1056/NEJMoa1311194 (Imperiale)
  16. 16. Physician & patient engagement team • Remove follow-up hassle from physicians • 24/7 contact center • Active patient reminders • Monthly compliance reporting to physicians 15
  17. 17. 16 Sales & marketing strategy PHYSICIANS 140 person sales team Med journal ads Hyper-targeted digital Direct mail/email PATIENTS Big-stage print Targeted digital Social media Search PAYERS CMS reimbursement Managed care team Compelling cost- effectiveness data
  18. 18. Experienced, focused sales team • 100 primary care reps, expanding in first half of 2015 • 11 health system reps • Average experience 10 years 17
  19. 19. Key Cologuard launch metrics 18 ①Q4 2014 revenue: $1.5 million ②More than 4,000 ordering physicians ③75% patient compliance rate* *The patient compliance rate is derived from the number of valid test results reported divided by the number of collection kits shipped to patients 60 or more days prior to December 31, 2014.
  20. 20. Cologuard public relations 19 Active effort to raise awareness of Cologuard • Cologuard featured in more than 1,000 unique news reports • More than 3 billion media impressions
  21. 21. Physician enrollment & ordering increasing 20 9,800+ physicians enrolled 42% ordering Data as of December 31, 2014
  22. 22. Sales & marketing tactics working % of Ordering Providers % of Orders 68% 32% 51 % 49% 21 Providers converted by sales force order more frequently Sales rep visit No rep visit Sales rep visit No rep visit
  23. 23. 37% 26% 10% 75% Returned with no compliance call Returned after compliance call 1 Returned after compliance call 2 Overall Compliance rate Active engagement program doubles participation 75% patient compliance rate 2x 22 +
  24. 24. Cologuard having positive effect on screening compliance Half of Cologuard users have never had a colonoscopy Never Screened or DRE Only 39% 10% Colonoscopy 51% FIT/FOBT Only 23 Source: Internal patient survey
  25. 25. 24 Impact of FIT/FOBT usage on ordering behavior *High FIT/FOBT defined as ≥100 FIT/FOBT tests annually More Cologuard orders from high FIT/FOBT providers*+25%
  26. 26. Medicare 43% Commercial Insurance 40% Medicaid 4% Military 2% Uninsured 10% Reimbursement efforts focused on commercial insurance Insurance Coverage (U.S., 50+) 25 Sources: US Census Bureau, 2012 estimate; AIS Directory of Healthplans: 2014; Kaiser Family Foundation 2014; Company Analysis Areas of Focus • Largest national and regional commercial insurers • States with insurance mandates • Health plans affiliated with health systems
  27. 27. Factors for Cologuard success in 2015 and beyond 26 Expanding reach and frequency with providers 1 USPSTF guideline inclusion will drive utilization • HEDIS quality measures • ACA insurance coverage mandate 2 Enable physician ordering via EMR systems 3
  28. 28. European launch of Cologuard 27 • Large, addressable market • High colon cancer rate (152K deaths annually) • Low screening rates ~20% • 136M people 50-75 years old • CE mark received December 2014 • Core team in place • Initial targets: UK, Germany, Austria, Switzerland & Italy
  29. 29. Other Lymphoma Leukemia Urinary Breast Genital Respiratory GI 145K Source: American Cancer Society 2013, Surveillance Research 2013 Estimated U.S. Cancer Deaths Digestive/GI cancers account for 25% of 580,000 U.S. cancer deaths 28
  30. 30. Exclusive Mayo Clinic collaboration on early detection of GI cancers 29 Colorectal Esophageal Pancreatic • Expand indication of Cologuard • High risk (e.g. family history, IBD) • 40-50 years old (long term) • Diagnosis of Barrett’s esophagus (a high-risk condition for cancer) • Early detection of esophageal cancer • Diagnose pancreatic cancer earlier and with greater accuracy
  31. 31. Financials and key milestones • Cash balance of $211 million as of September 30, 2014 • $100-million offering closed in December 2014 • $1.5 million in revenue during Q4 2014 (unaudited) • 4,000+ ordering physicians as of December 31, 2014 • U.S. Preventive Services Task Force update • Q4 earnings call late February 30
  32. 32. 31 Grow Cologuar d Develop Pipeline World Class Service Our goals for 2015

×